ACADACADIA Pharmaceuticals Inc.

$4B

Q1 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$90M+43.1% YoY

Gross Profit

$85M94.5% margin

Operating Income

-$90M-99.4% margin

Net Income

-$88M-97.7% margin

EPS (Diluted)

$-0.57

QoQ Revenue Growth

-8.4%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$50M

Stock-Based Comp.

$22M

Balance Sheet

Total Assets

$747M

Total Liabilities

$109M

Stockholders' Equity

$638M

Cash & Equivalents

$173M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$90M	$63M	+43.1%
Gross Profit	$85M	$58M	+45.8%
Operating Income	-$90M	-$88M	-2.1%
Net Income	-$88M	-$85M	-3.2%

ACAD Q1 2020 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena